Patients who have received vaccinations against shingles or respiratory syncytial virus (RSV) have shown a reduced risk of developing dementia, a new study reveals. This study contributes to the growing evidence suggesting that the protective benefits against dementia may be linked to the adjuvant system used in creating the vaccines.
The research, published in npj Vaccines, was led by Paul J. Harrison and his team from the University of Oxford. Their previous study demonstrated that the recombinant shingles vaccine was associated with a lowered risk of dementia compared to the live version of the vaccine. The efficacy of the live vaccine has been questioned, leading to its discontinuation in several countries, including the United States.
The authors proposed two hypotheses based on their previous findings. The first suggests that shingles infection itself could increase the risk of dementia, making the recombinant vaccine more effective at preventing dementia by preventing shingles. The second hypothesis revolves around the AS01 adjuvant system in the vaccine providing protection against dementia. Adjuvants are substances that enhance the immune response to vaccines.
Further investigation was conducted by the researchers to delve into the potential impact of the AS01 adjuvant system. They analyzed dementia rates in individuals who received vaccines with the AS01 adjuvant, targeting both shingles and RSV. The study utilized electronic health records from over 400,000 patients to evaluate dementia risk in these two vaccine cohorts.
Three groups were formed based on vaccination status: those who received only the shingles vaccine, those who received the RSV vaccine, and those who received both vaccines. These groups were compared with matched controls who had the flu vaccine but not the shingles or RSV vaccines. The study participants had a mean age ranging from 69.2 to 72.8 years, with a higher percentage of females in each group.
The analysis excluded dementia diagnoses within three months of vaccination to account for pre-existing undiagnosed dementia. The results revealed that individuals who received the AS101 vaccine had a significantly lower risk of dementia compared to those who only received the flu vaccine.
The researchers employed the ratio of restricted mean time lost (RMTL) as a metric to assess dementia risk, with scores below 1.0 indicating a decreased risk. Those who received both the RSV and shingles vaccines exhibited an RMTL ratio of 0.63, while the ratios for individuals who received only the shingles or RSV vaccines were 0.82 and 0.71, respectively.
Despite the clear association between AS01 vaccination and reduced dementia risk, the exact mechanism behind this protective effect remains unclear. The authors proposed that the AS01 system may independently lower dementia risk by preventing respiratory infections like shingles and RSV, which have been linked to increased dementia risk. However, the rapid onset of the protective benefits post-vaccination suggests alternative mechanisms.
One such mechanism could involve AS01 protecting against dementia through specific immunological pathways, potentially involving toll-like receptor 4 stimulation with monophosphoryl lipid A (MPL), a component of the AS01 system. Studies in mice have shown that MPL can improve Alzheimer’s pathology, indicating a potential pathway for the protective effects seen in the study.
While the precise reasons for the protective effects of AS01 vaccination against dementia require further investigation, the findings highlight the importance of exploring these mechanisms to develop strategies for preventing neurodegenerative disorders like Alzheimer’s disease.
In conclusion, vaccinations against shingles and RSV, particularly those utilizing the AS01 adjuvant system, have shown promise in lowering the risk of dementia. Understanding the underlying mechanisms driving this protective effect could pave the way for innovative preventive strategies in combating neurodegenerative diseases.
Takeaways:
– Vaccination against shingles and RSV with the AS01 adjuvant system may reduce the risk of dementia.
– The protective benefits of vaccination may involve preventing respiratory infections and activating specific immunological pathways.
– Further research is needed to elucidate the exact mechanisms by which vaccinations lower dementia risk.
– Exploring the potential of vaccines in preventing neurodegenerative disorders is crucial for future healthcare strategies.
Read more on managedhealthcareexecutive.com